Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 6/2017

01.12.2017 | Review Article

Pediatric Psoriasis

verfasst von: Maria Relvas, Tiago Torres

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a chronic inflammatory systemic disease associated with an important physical and physiological burden. It primarily affects the skin, but it is associated with several serious medical co-morbidities. One third of total psoriatic cases have their onset during the pediatric age, although some of them may not be diagnosed until the patient reaches adulthood. Additionally, in the pediatric age, there is an association with several medical co-morbidities; thus, an early recognition of the disease and a subsequent appropriate approach may delay or even prevent considerable co-morbidities. Because children are not just ‘small adults’, specific guidelines for the diagnosis, management, and treatment of psoriasis are of extreme importance. However, these guidelines are still lacking in this age group. Most of the psoriasis treatments used in adults are not officially approved for the pediatric age and require off-label prescription. Moreover, efficacy and safety studies are lacking in this population, especially with long-term follow-up and outcomes. Many biologic agents have been recently approved for the treatment of psoriasis in children, while others are currently being studied. This bibliographic review aims to summarize the most relevant aspects, as well as updated information about the epidemiology, pathogenesis, clinical features, diagnosis, co-morbidities and treatment of pediatric psoriasis.
Literatur
1.
Matteo M, Maddalena N, Balato A, et al. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11(1):10–26.CrossRef
2.
3.
Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450–6.PubMedCrossRef
4.
Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–87.PubMedCrossRef
5.
Silverberg NB. Update on pediatric psoriasis. Cutis. 2015;95(3):147–52.PubMed
6.
Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–6.PubMedCrossRef
7.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMedCrossRef
8.
Chiam LY, de Jager ME, Giam YC, et al. Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol. 2011;164(5):1101–3.PubMedCrossRef
9.
Choon SE, Ngim CF, Premaa S, et al. Clinico-epidemiological profile, including body mass index of Malaysian children with psoriasis. Med J Malays. 2016;71(4):171–6.
10.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.PubMedCrossRef
11.
Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs. 2015;17(5):373–84.CrossRef
12.
13.
Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.PubMedCrossRef
14.
Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet. 2002;71(3):554–64.PubMedPubMedCentralCrossRef
15.
Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.PubMedPubMedCentralCrossRef
16.
Romiti R, Maragno L, Arnone M, Takahashi MD. Psoriasis in childhood and adolescence. An Bras Dermatol. 2009;84(1):9–20.PubMedCrossRef
17.
Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients: an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol. 2006;126(4):740–5.PubMedCrossRef
18.
Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120(4):627–32.PubMedCrossRef
19.
Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867–73.PubMedCrossRef
20.
Silverberg NB. Update on pediatric psoriasis, part 1: clinical features and demographics. Cutis. 2010;86(3):118–24.PubMed
21.
Li Y, Begovich AB. Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. Semin Immunol. 2009;21(6):318–27.PubMedCrossRef
22.
Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187–92.PubMedCrossRef
23.
Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–8.PubMedCrossRef
24.
Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol. 2003;149(3):530–4.PubMedCrossRef
25.
Perez-Lorenzo R, Zambrano-Zaragoza JF, Saul A, et al. Autoantibodies to autologous skin in guttate and plaque forms of psoriasis and cross-reaction of skin antigens with streptococcal antigens. Int J Dermatol. 1998;37(7):524–31.PubMedCrossRef
26.
Besgen P, Trommler P, Vollmer S, Prinz JC. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. J Immunol. 2010;184(9):5392–402.PubMedCrossRef
27.
Santamaria-Babi LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol. 2004;14(1):13–8.PubMed
28.
Ferran M, Galvan AB, Rincon C, et al. Streptococcus induces circulating CLA(+) memory T-cell-dependent epidermal cell activation in psoriasis. J Invest Dermatol. 2013;133(4):999–1007.PubMedCrossRef
29.
Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244–1252 e2.PubMedPubMedCentralCrossRef
30.
Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: a prospective case series. J Am Acad Dermatol. 2016;75(5):889–96.PubMedPubMedCentralCrossRef
31.
Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: a systematic review. J Am Acad Dermatol. 2015;72(2):261–75.PubMedCrossRef
32.
Gupta MA, Gupta AK, Watteel GN. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol. 1996;135(5):859–60.PubMedCrossRef
33.
Ozden MG, Tekin NS, Gurer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case–control study. Pediatr Dermatol. 2011;28(3):306–12.PubMedCrossRef
34.
Gul Mert G, Incecik F, Gunasti S, et al. Psoriasiform drug eruption associated with sodium valproate. Case Rep Pediatr. 2013;2013:823469.PubMedPubMedCentral
35.
Busch AL, Landau JM, Moody MN, Goldberg LH. Pediatric psoriasis. Skin Ther Lett. 2012;17(1):5–7.
36.
Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010;49(12):1351–61.PubMedCrossRef
37.
Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14(3):195–213.PubMedCrossRef
38.
Tollefson MM. Diagnosis and management of psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–77.PubMedCrossRef
39.
Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577–83.PubMedPubMedCentralCrossRef
40.
Bryld LE, Sorensen TI, Andersen KK, et al. High body mass index in adolescent girls precedes psoriasis hospitalization. Acta Derm Venereol. 2010;90(5):488–93.PubMedCrossRef
41.
42.
Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27.PubMedCrossRef
43.
44.
Chiricozzi A, Suarez-Farinas M, Fuentes-Duculan J, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136–45.PubMedCrossRef
45.
Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(Suppl. 1):9–20.PubMedCrossRef
46.
Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.PubMedPubMedCentralCrossRef
47.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.PubMedCrossRef
48.
49.
Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin. 1998;16(3):593–608.PubMedCrossRef
50.
Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424–8.PubMedPubMedCentralCrossRef
51.
Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 1):15–21.PubMedCrossRef
52.
Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr. 1988;113(6):1037–9.PubMedCrossRef
53.
Hani AF, Prakasa E, Nugroho H, et al. Body surface area measurement and soft clustering for PASI area assessment. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:4398–401.PubMed
54.
Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931–7.PubMedCrossRef
55.
Finlay AY. Avoiding palmar ambiguity in the PREPI: a handprint is approximately 1% body surface area. Br J Dermatol. 2011;164(3):679 (author reply 80).PubMed
56.
Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666.PubMedCrossRef
57.
Stahle M, Atakan N, Boehncke WH, et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges. 2010;8(10):812–8.PubMed
58.
Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524–8.PubMedCrossRef
59.
Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol. 2012;166(6):1198–205.PubMedCrossRef
60.
Chang MW, Nakrani R. Six children with allergic contact dermatitis to methylisothiazolinone in wet wipes (baby wipes). Pediatrics. 2014;133(2):e434–8.PubMedCrossRef
61.
Pietrzak A, Grywalska E, Walankiewicz M, et al. Psoriasis and metabolic syndrome in children: current data. Clin Exp Dermatol. 2017;42(2):131–6.PubMedCrossRef
62.
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–7.PubMedCrossRef
63.
Mahe E, Maccari F, Beauchet A, et al. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. Br J Dermatol. 2013;169(4):889–95.PubMedCrossRef
64.
Au SC, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012;66(6):1012–3.PubMedCrossRef
65.
Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–76.PubMedPubMedCentralCrossRef
66.
Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.PubMedCrossRef
67.
Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol. 2011;147(4):419–24.PubMedCrossRef
68.
Prahalad S, McCracken CE, Ponder LA, et al. Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry. Pediatr Rheumatol Online J. 2016;14(1):14.PubMedPubMedCentralCrossRef
69.
Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl. 2):ii14–7.PubMedPubMedCentral
70.
71.
Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8.PubMedCrossRef
72.
Pourchot D, Bodemer C, Phan A, et al. Nail psoriasis: a systematic evaluation in 313 children with psoriasis. Pediatr Dermatol. 2017;34(1):58–63.PubMedCrossRef
73.
Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis: a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–6.PubMedCrossRef
74.
Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452–7.PubMedCrossRef
75.
Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233–9.PubMedPubMedCentralCrossRef
76.
Mercan S, Kivanc Altunay I. Psychodermatology: a collaboration between psychiatry and dermatology. Turk Psikiyatri Derg. 2006;17(4):305–13.PubMed
77.
de Jager ME, De Jong EM, Evers AW, et al. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736–7.PubMedCrossRef
78.
Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145–51.PubMedCrossRef
79.
Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657 e1–2.PubMedCrossRef
80.
Akay A, Pekcanlar A, Bozdag KE, et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol. 2002;16(4):347–52.PubMedCrossRef
81.
Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155–9 (quiz 60–1).PubMedCrossRef
82.
Manzoni AP, Weber MB, Nagatomi AR, et al. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013;88(6):894–9.PubMedPubMedCentralCrossRef
83.
Lin VW. Tough-skinned kids: identifying psychosocial effects of psoriasis and helping pediatric patients and families cope. J Pediatr Nurs. 2012;27(5):563–72.PubMedCrossRef
84.
Sticherling M, Augustin M, Boehncke WH, et al. Therapy of psoriasis in childhood and adolescence: a German expert consensus. J Dtsch Dermatol Ges. 2011;9(10):815–23.PubMed
85.
Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1–7.PubMedCrossRef
86.
Kiken DA, Silverberg NB. Atopic dermatitis in children, part 2: treatment options. Cutis. 2006;78(6):401–6.PubMed
87.
Silverberg NB. Update on pediatric psoriasis. Part 2: therapeutic management. Cutis. 2010;86(4):172–6.PubMed
88.
Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121(1):63–7.PubMedCrossRef
89.
O’Neill JL, Feldman SR. Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc). 2010;46(5):351–60.PubMedCrossRef
90.
Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–3.PubMedCrossRef
91.
van Geel MJ, Mul K, Oostveen AM, et al. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363–9.PubMedCrossRef
92.
Oostveen AM, de Jong EM, Donders AR, et al. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice. J Eur Acad Dermatol Venereol. 2015;29(6):1193–7.PubMedCrossRef
93.
Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. Br J Dermatol. 2014;171(6):1470–7.PubMedPubMedCentralCrossRef
94.
Cordoro KM. Topical therapy for the management of childhood psoriasis: part I. Skin Ther Lett. 2008;13(3):1–3.
95.
Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.PubMedCrossRef
96.
Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713–6.PubMedCrossRef
97.
Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–41.PubMedCrossRef
98.
Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380–6.PubMedCrossRef
99.
Diluvio L, Campione E, Paterno EJ, et al. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332–3.PubMedCrossRef
100.
Cram DL. Psoriasis: treatment with a tar gel. Cutis. 1976;17(6):1197–8, 202–3.
101.
Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol. 2009;61(2):294–302.PubMedCrossRef
102.
Cordoro KM. Systemic and light therapies for the management of childhood psoriasis: part II. Skin Ther Lett. 2008;13(4):1–3.
103.
Dawe RS, Wainwright NJ, Cameron H, Ferguson J. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol. 1998;138(5):833–9.PubMedCrossRef
104.
Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed. 2000;16(5):202–6.PubMedCrossRef
105.
Holme SA, Anstey AV. Phototherapy and PUVA photochemotherapy in children. Photodermatol Photoimmunol Photomed. 2004;20(2):69–75.PubMedCrossRef
106.
Marqueling AL, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin. 2013;31(2):267–88.PubMedCrossRef
107.
de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–30.PubMedCrossRef
108.
Coven TR, Burack LH, Gilleaudeau R, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133(12):1514–22.PubMedCrossRef
109.
Lara-Corrales I, Ramnarine S, Lansang P. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25–33.PubMedPubMedCentral
110.
al-Fouzan AS, Nanda A. UVB phototherapy in childhood psoriasis. Pediatr Dermatol. 1995;12(1):66.PubMedCrossRef
111.
Jain VK, Aggarwal K, Jain K, Bansal A. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46(3):320–2.PubMedCrossRef
112.
Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20(1):71–7.PubMedCrossRef
113.
Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13(5):406–9.PubMedCrossRef
114.
Diffey BL, Farr PM. The challenge of follow-up in narrowband ultraviolet B phototherapy. Br J Dermatol. 2007;157(2):344–9.PubMedCrossRef
115.
Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149(1):146–50.PubMedCrossRef
116.
Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol. 2000;42(3):493–5.PubMedCrossRef
117.
Carrozza P, Hausermann P, Nestle FO, et al. Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis: an open pilot study. Dermatology. 2000;200(1):35–9.PubMedCrossRef
118.
Berne B, Blom I, Spangberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base: a single-blind controlled study. Acta Derm Venereol. 1990;70(6):474–7.PubMed
119.
Wolff K. Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol. 1990;122(Suppl. 36):117–25.PubMedCrossRef
120.
Schiener R, Brockow T, Franke A, et al. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol. 2007;143(5):586–96.PubMedCrossRef
121.
Delrosso G, Bornacina C, Farinelli P, et al. Bath PUVA and psoriasis: is a milder treatment a worse treatment? Dermatology. 2008;216(3):191–3.PubMedCrossRef
122.
National Psoriasis Foundation. Light therapy. OR, USA, 2014.
123.
Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010;29(1):20–7.PubMedCrossRef
124.
Paller AS. Dermatologic uses of methotrexate in children: indications and guidelines. Pediatr Dermatol. 1985;2(3):238–43.PubMedCrossRef
125.
Rahman SI, Siegfried E, Flanagan KH, Armbrecht ES. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol. 2014;70(2):252–6.PubMedCrossRef
126.
Dervieux T, Orentas Lein D, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49(10):1632–41.PubMedCrossRef
127.
Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 1995;22(11):2072–7.PubMed
128.
Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol. 1993;20(10):1764–8.PubMed
129.
Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol. 1987;17(6):1055–6.PubMedCrossRef
130.
van Geel MJ, Mul K, de Jager ME, et al. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol. 2015;29(3):425–37.PubMedCrossRef
131.
Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005;6(10):1725–34.PubMedCrossRef
132.
Di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis. Pediatr Dermatol. 2016;33(5):530–5.PubMedCrossRef
133.
Pereira TM, Vieira AP, Fernandes JC, Sousa-Basto A. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol. 2006;20(6):651–6.PubMedCrossRef
134.
Alli N, Gungor E, Karakayali G, et al. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754–5.PubMedCrossRef
135.
Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14(2):113–8.CrossRef
136.
Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137(11):1532–3.PubMed
137.
Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–8.PubMedCrossRef
138.
Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306–8.PubMedCrossRef
139.
140.
Bianchi L, Del Duca E, Romanelli M, et al. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol. 2016;12(9):1121–8.PubMedCrossRef
141.
142.
Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6(10):561–71.PubMedCrossRef
143.
Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23(1):67–71.PubMedCrossRef
144.
Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154(1):181–3.PubMedCrossRef
145.
Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–51.PubMedCrossRef
146.
147.
148.
149.
Malkonen T, Wikstrom A, Heiskanen K, et al. Skin reactions during anti-TNFalpha therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20(8):1309–15.PubMedCrossRef
150.
151.
Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.PubMedCrossRef
152.
Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–7.PubMedCrossRef
153.
Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51.PubMedCrossRef
154.
155.
Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.PubMedCrossRef
156.
Pharmaceuticals N. A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis. https://​clinicaltrials.​gov/​ct2/​show/​NCT02471144. Cited 2017 April 19.
157.
Metadaten
Titel
Pediatric Psoriasis
verfasst von
Maria Relvas
Tiago Torres
Publikationsdatum
01.12.2017
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0294-9

Weitere Artikel der Ausgabe 6/2017

American Journal of Clinical Dermatology 6/2017 Zur Ausgabe

Research letter

Improvement of Rosacea During Acyclovir Treatment: A Case Report

Adis Drug Evaluation

Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis

Original Research Article

Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey

Systematic Review

Probiotics, Prebiotics, and Synbiotics for the Treatment and Prevention of Adult Dermatological Diseases

Acknowledgement to Referees

Acknowledgement to Referees

Original Research Article

Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

16.04.2024 | DGIM 2024 | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise